MMP9 and familial pancreatic carcinoma: Previous clinical studies using a pan-MMP inhibitor showed overexpression of MMP9 in patients with pancreatic cancer.16 17 A phase 1 study was conducted to examine the safety and efficacy of andecaliximab with gemcitabine plus nab-paclitaxel in patients with advanced pancreatic cancer.18 19 This combination therapy also resulted in favorable safety and clinical activity.